Literature DB >> 24534724

Involvement of interleukin-17A-induced expression of heat shock protein 47 in intestinal fibrosis in Crohn's disease.

Yusuke Honzawa1, Hiroshi Nakase1, Masahiro Shiokawa1, Takuya Yoshino1, Hirotsugu Imaeda2, Minoru Matsuura1, Yuzo Kodama1, Hiroki Ikeuchi3, Akira Andoh2, Yoshiharu Sakai4, Kazuhiro Nagata5, Tsutomu Chiba1.   

Abstract

OBJECTIVE: Intestinal fibrosis is a clinically important issue in Crohn's disease (CD). Heat shock protein (HSP) 47 is a collagen-specific molecular chaperone involved in fibrotic diseases. The molecular mechanisms of HSP47 induction in intestinal fibrosis related to CD, however, remain unclear. Here we investigated the role of interleukin (IL)-17A-induced HSP47 expression in intestinal fibrosis in CD.
DESIGN: Expressions of HSP47 and IL-17A in the intestinal tissues of patients with IBD were determined. HSP47 and collagen I expressions were assessed in intestinal subepithelial myofibroblasts (ISEMFs) isolated from patients with IBD and CCD-18Co cells treated with IL-17A. We examined the role of HSP47 in IL-17A-induced collagen I expression by administration of short hairpin RNA (shRNA) to HSP47 and investigated signalling pathways of IL-17A-induced HSP47 expression using specific inhibitors in CCD-18Co cells.
RESULTS: Gene expressions of HSP47 and IL-17A were significantly elevated in the intestinal tissues of patients with active CD. Immunohistochemistry revealed HSP47 was expressed in α-smooth muscle actin (α-SMA)-positive cells and the number of HSP47-positive cells was significantly increased in the intestinal tissues of patients with active CD. IL-17A enhanced HSP47 and collagen I expressions in ISEMFs and CCD-18Co cells. Knockdown of HSP47 in these cells resulted in the inhibition of IL-17A-induced collagen I expression, and analysis of IL-17A signalling pathways revealed the involvement of c-Jun N-terminal kinase in IL-17A-induced HSP47 expression.
CONCLUSIONS: IL-17A-induced HSP47 expression is involved in collagen I expression in ISEMFs, which might contribute to intestinal fibrosis in CD. Published by the BMJ Publishing Group Limited. For permission to use (where not already granted under a licence) please go to http://group.bmj.com/group/rights-licensing/permissions.

Entities:  

Keywords:  Crohn's disease (CD); Fibrosis; Heat shock protein (HSP); Myofibroblasts

Mesh:

Substances:

Year:  2014        PMID: 24534724     DOI: 10.1136/gutjnl-2013-305632

Source DB:  PubMed          Journal:  Gut        ISSN: 0017-5749            Impact factor:   23.059


  27 in total

Review 1.  Interleukin-17: Friend or foe in organ fibrosis.

Authors:  Kritika Ramani; Partha S Biswas
Journal:  Cytokine       Date:  2019-02-14       Impact factor: 3.861

2.  HSP47 promotes metastasis of breast cancer by interacting with myosin IIA via the unfolded protein response transducer IRE1α.

Authors:  Akihiro Yoneda; Kenjiro Minomi; Yasuaki Tamura
Journal:  Oncogene       Date:  2020-05-04       Impact factor: 9.867

3.  Deletion of the collagen-specific molecular chaperone Hsp47 causes endoplasmic reticulum stress-mediated apoptosis of hepatic stellate cells.

Authors:  Kunito Kawasaki; Ryo Ushioda; Shinya Ito; Kazuo Ikeda; Yusaku Masago; Kazuhiro Nagata
Journal:  J Biol Chem       Date:  2014-12-18       Impact factor: 5.157

4.  Effect of Homocysteine on the Differentiation of CD4+ T Cells into Th17 Cells.

Authors:  Xin Gao; Jin Li; Min Chen
Journal:  Dig Dis Sci       Date:  2018-07-04       Impact factor: 3.199

Review 5.  Controversial Contribution of Th17/IL-17 Toward the Immune Response in Intestinal Fibrosis.

Authors:  Giovanni Latella; Angelo Viscido
Journal:  Dig Dis Sci       Date:  2020-05       Impact factor: 3.199

Review 6.  Roles of the endoplasmic reticulum-resident, collagen-specific molecular chaperone Hsp47 in vertebrate cells and human disease.

Authors:  Shinya Ito; Kazuhiro Nagata
Journal:  J Biol Chem       Date:  2018-12-12       Impact factor: 5.157

7.  IL-17-induced HIF1α drives resistance to anti-PD-L1 via fibroblast-mediated immune exclusion.

Authors:  Xing Chen; Junjie Zhao; Tomasz Herjan; Lingzi Hong; Yun Liao; Caini Liu; Kommireddy Vasu; Han Wang; Austin Thompson; Paul L Fox; Brian R Gastman; Xiao Li; Xiaoxia Li
Journal:  J Exp Med       Date:  2022-04-07       Impact factor: 17.579

8.  A small-molecule compound inhibits a collagen-specific molecular chaperone and could represent a potential remedy for fibrosis.

Authors:  Shinya Ito; Koji Ogawa; Koh Takeuchi; Motoki Takagi; Masahito Yoshida; Takatsugu Hirokawa; Shoshiro Hirayama; Kazuo Shin-Ya; Ichio Shimada; Takayuki Doi; Naoki Goshima; Tohru Natsume; Kazuhiro Nagata
Journal:  J Biol Chem       Date:  2017-10-12       Impact factor: 5.157

Review 9.  Development of antifibrotic therapy for stricturing Crohn's disease: lessons from randomized trials in other fibrotic diseases.

Authors:  Si-Nan Lin; Ren Mao; Chenchen Qian; Dominik Bettenworth; Jie Wang; Jiannan Li; David H Bruining; Vipul Jairath; Brian G Feagan; Min-Hu Chen; Florian Rieder
Journal:  Physiol Rev       Date:  2021-09-27       Impact factor: 37.312

Review 10.  Novel mechanisms and clinical trial endpoints in intestinal fibrosis.

Authors:  Jie Wang; Sinan Lin; Jonathan Mark Brown; David van Wagoner; Claudio Fiocchi; Florian Rieder
Journal:  Immunol Rev       Date:  2021-05-16       Impact factor: 10.983

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.